Yttrium-90 Radioembolization and Tumor Hypoxia: Gas-challenge BOLD Imaging in the VX2 Rabbit Model of Hepatocellular Carcinoma

2020 ◽  
Author(s):  
Andrew C. Gordon ◽  
Sarah B. White ◽  
Vanessa L. Gates ◽  
Daniel Procissi ◽  
Kathleen R. Harris ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Hypoxia ◽  
Rabbit Model ◽  
Bold Imaging ◽  
Yttrium 90

Measuring radiation exposure of operators engaged in the yttrium-90 microsphere radioembolization treatment of hepatocellular carcinoma patients

Optik ◽  
2021 ◽  
pp. 167392
Author(s):  
Jina Shim ◽  
Gyoung Min Kim ◽  
Do Young Kim ◽  
Mi Jin Yun ◽  
Soo Hyun Seo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Exposure ◽  
Yttrium 90

scholarly journals Pathologic validation of an yttrium-90 trans-arterial radioembolization dosimetry: a case report

2021 ◽  
Vol 2021 (4) ◽  
Author(s):  
Jacqueline B Baikovitz ◽  
Lindsay Thornton ◽  
Monica T Garcia-Buitrago ◽  
Alan S Livingstone ◽  
Matthew T Studenski ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Liver Resection ◽  
Pathologic Response ◽  
Clinical Scenario ◽  
Complete Pathologic Response ◽  
Pathological Findings ◽  
Rigorous Approach ◽  
Yttrium 90

Abstract Yttrium-90 (Y-90) trans-arterial radioembolization (TARE) is used in the management of unresectable hepatocellular carcinoma (HCC). During the last 5 years, dosimetry software has been developed to allow for a more rigorous approach of dose prescription in Y-90 TARE. We present here a case study of a 77-year-old woman diagnosed with HCC, who underwent a Y-90 TARE as a bridge procedure to liver resection. This clinical scenario represents a unique opportunity to illustrate the predictive value of dosimetric findings correlating dosimetry with pathological findings. In this case, Y-90 TARE dosimetry was predictive of treatment response in which the tumor received a mean dose of 156 Gy and demonstrated a complete pathologic response.

scholarly journals Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma

2016 ◽  
Vol 33 (5) ◽  
pp. 699-714 ◽  
Author(s):  
Joseph Ralph Kallini ◽  
Ahmed Gabr ◽  
Riad Salem ◽  
Robert J. Lewandowski
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Radioembolization ◽  
Yttrium 90

Radioembolization for Rare Metastatic Disease

2021 ◽  
Author(s):  
Andrew S. Niekamp ◽  
Govindarajan Narayanan ◽  
Brian J. Schiro ◽  
Constantino Pena ◽  
Alex Powell ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatocellular Carcinoma ◽  
Metastatic Colorectal Cancer ◽  
Treatment Modality ◽  
Treatment Options ◽  
Efficacy And Safety ◽  
Multiple Tumor ◽  
Tumor Types ◽  
Hepatic Malignancies ◽  
Yttrium 90

AbstractRadioembolization has become a widespread treatment modality for both primary and metastatic hepatic malignancies. Although the majority of data and indication for yttrium-90 radioembolization have been for hepatocellular carcinoma and metastatic colorectal cancer, radioembolization with yttrium-90 has rapidly expanded into the treatment options for multiple tumor types with metastases to the liver. This article reviews the clinical data and expanding utilization of radioembolization for rare metastatic diseases with an emphasis on efficacy and safety.

Sign in / Sign up

Export Citation Format

Share Document